Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | CA2 | P00918 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27183141 | 0.84 | HPGD (0.72) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL24667482 | 0.84 | HPGD (0.72) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL21596182 | 0.84 | HPGD (0.72) | HPGDRECQLCA1CA2ALDH1A1 | |
| Hydrazine SCHEMBL28785858 | 0.84 | CA1 (0.75) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL8599690 | 0.83 | HPGD (0.70) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL13064478 | 0.83 | HPGD (0.80) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL27929690 | 0.83 | CA1 (0.73) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL5779034 | 0.83 | HPGD (0.72) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL63833 | 0.82 | HPGD (0.70) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL22225675 | 0.82 | HPGD (0.68) | HPGDRECQLCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-109071446-B | Organic reaction in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkylcellulose | 艾伯维德国有限责任两合公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022035763-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1620397-A1 | HYDROXAMIC ACIDS USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094376-A1 | HYDROXAMIC ACIDS USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | HPGD 1300/4885RECQL 915/4885CA1 3472/4885 |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HPGD 2258/4885RECQL 2967/4885CA1 3605/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HPGD 2258/4885RECQL 2967/4885CA1 3605/4885 |
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | MKI67, PCNA, CCNA1 | HPGD 113/4885RECQL 837/4885CA1 3048/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HPGD 2258/4885RECQL 2967/4885CA1 3605/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HPGD 2258/4885RECQL 2967/4885CA1 3605/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | HPGD 1300/4885RECQL 915/4885CA1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.